Literature DB >> 9556560

Reaction of O6-benzylguanine-resistant mutants of human O6-alkylguanine-DNA alkyltransferase with O6-benzylguanine in oligodeoxyribonucleotides.

A E Pegg1, S Kanugula, S Edara, G T Pauly, R C Moschel, K Goodtzova.   

Abstract

Inactivation of the human DNA repair protein, O6-alkylguanine-DNA alkyltransferase (AGT), by O6-benzylguanine renders tumor cells susceptible to killing by alkylating agents. AGT mutants resistant to O6-benzylguanine can be made by converting Pro140 to an alanine (P140A) or Gly156 to an alanine (G156A). These mutations had a much smaller effect on the reaction with O6-benzylguanine when it was incorporated into a short single-stranded oligodeoxyribonucleotide. Such oligodeoxyribonucleotides could form the basis for the design of improved AGT inhibitors. AGT and mutants P140A and G156A preferentially reacted with O6-benzylguanine when incubated with a mixture of two 16-mer oligodeoxyribonucleotides, one containing O6-benzylguanine and the other, O6-methylguanine. When the 6 amino acids located in positions 159-164 in AGT were replaced by the equivalent sequence from the Escherichia coli Ada-C protein (mutant AGT/6ada) the preference for benzyl repair was eliminated. Further mutation incorporating the P140A change into AGT/6ada giving mutant P140A/6ada led to a protein that resembled Ada-C in preference for the repair of methyl groups, but P140A/6ada did not differ from P140A in reaction with the free base O6-benzylguanine. Changes in the AGT active site pocket can therefore affect the preference for repair of O6-benzyl or -methyl groups when present in an oligodeoxyribonucleotide without altering the reaction with free O6-benzylguanine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9556560     DOI: 10.1074/jbc.273.18.10863

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model.

Authors:  Meredith K Chuk; Diane E Cole; Cynthia McCully; Natalia A Loktionova; Anthony E Pegg; Robert J Parker; Gary Pauly; Brigitte C Widemann; Frank M Balis; Elizabeth Fox
Journal:  Cancer Chemother Pharmacol       Date:  2010-08-20       Impact factor: 3.333

2.  Active and alkylated human AGT structures: a novel zinc site, inhibitor and extrahelical base binding.

Authors:  D S Daniels; C D Mol; A S Arvai; S Kanugula; A E Pegg; J A Tainer
Journal:  EMBO J       Date:  2000-04-03       Impact factor: 11.598

3.  Interactions of human O6-alkylguanine-DNA alkyltransferase (AGT) with short single-stranded DNAs.

Authors:  Joseph J Rasimas; Sambit R Kar; Anthony E Pegg; Michael G Fried
Journal:  J Biol Chem       Date:  2006-11-30       Impact factor: 5.157

Review 4.  Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy.

Authors:  Lucy Gossage; Srinivasan Madhusudan
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

5.  The O6-methyguanine-DNA methyltransferase inhibitor O6-benzylguanine enhanced activity of temozolomide + irinotecan against models of high-risk neuroblastoma.

Authors:  Ashly Hindle; Balakrishna Koneru; Monish Ram Makena; Lluis Lopez-Barcons; Wan Hsi Chen; Thinh H Nguyen; C Patrick Reynolds
Journal:  Anticancer Drugs       Date:  2021-03-01       Impact factor: 2.389

6.  O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.

Authors:  S Ma; S Egyházi; T Ueno; C Lindholm; E L Kreklau; U Stierner; U Ringborg; J Hansson
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

7.  Fluorogenic Real-Time Reporters of DNA Repair by MGMT, a Clinical Predictor of Antitumor Drug Response.

Authors:  Andrew A Beharry; Zachary D Nagel; Leona D Samson; Eric T Kool
Journal:  PLoS One       Date:  2016-04-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.